Spyre Therapeutics (SYRE) Notes Payables (2023 - 2026)

Spyre Therapeutics' Notes Payables history runs 4 years deep, the most recent figure standing at $50.3 million for Q1 2026.

• Quarterly Notes Payables rose 17.4% year-over-year to $50.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.3 million (up 17.4% YoY) and the FY2025 annual result came in at $22.8 million, down 9.01% from the prior year.
• Notes Payables was $50.3 million for Q1 2026 at Spyre Therapeutics, up from $22.8 million in the prior quarter.
• Across five years, Notes Payables topped out at $59.9 million in Q2 2025 and bottomed at $1.4 million in Q4 2023.
• A 4-year average of $22.6 million and a median of $21.8 million in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2024 — Notes Payables slumped 87.31% — and 2025, when it jumped 2168.94%.
• Spyre Therapeutics' Notes Payables stood at $1.4 million in 2023, then surged by 1704.32% to $25.1 million in 2024, then declined by 9.01% to $22.8 million in 2025, then jumped by 120.25% to $50.3 million in 2026.
• Business Quant data shows SYRE's Notes Payables at $50.3 million in Q1 2026, $22.8 million in Q4 2025, and $11.0 million in Q3 2025.